Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy.

Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW.

Sci Rep. 2020 Feb 14;10(1):3000. doi: 10.1038/s41598-020-59902-7.

2.

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases.

Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP.

Cancer Gene Ther. 2019 Jun 3. doi: 10.1038/s41417-019-0104-z. [Epub ahead of print]

PMID:
31155611
3.

YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells.

Balkhi MY, Wittmann G, Xiong F, Junghans RP.

iScience. 2018 Apr 27;2:105-122. doi: 10.1016/j.isci.2018.03.009. Epub 2018 Apr 11.

4.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

5.

STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.

Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, Espat NJ, Junghans RP, Katz SC.

Oncogene. 2019 Jan;38(4):533-548. doi: 10.1038/s41388-018-0449-z. Epub 2018 Aug 29.

PMID:
30158673
6.

Engineering Axl specific CAR and SynNotch receptor for cancer therapy.

Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW.

Sci Rep. 2018 Mar 1;8(1):3846. doi: 10.1038/s41598-018-22252-6. Erratum in: Sci Rep. 2020 Feb 14;10(1):3000.

7.

Oral Tranexamic Acid Reduces Transfusions in Total Knee Arthroplasty.

Perreault RE, Fournier CA, Mattingly DA, Junghans RP, Talmo CT.

J Arthroplasty. 2017 Oct;32(10):2990-2994. doi: 10.1016/j.arth.2017.03.063. Epub 2017 Apr 6.

PMID:
28757131
8.

Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression.

Guha P, Cunetta M, Somasundar P, Espat NJ, Junghans RP, Katz SC.

J Leukoc Biol. 2017 Aug;102(2):201-208. doi: 10.1189/jlb.5HI0716-322RR. Epub 2017 May 25.

9.

The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Junghans RP.

Cancer Gene Ther. 2017 Mar;24(3):89-99. doi: 10.1038/cgt.2016.82. No abstract available.

PMID:
28392558
10.

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response.

Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, Cohen SI.

Prostate. 2016 Oct;76(14):1257-70. doi: 10.1002/pros.23214. Epub 2016 Jun 21.

PMID:
27324746
11.

Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.

Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, Katz SC.

Cancer Gene Ther. 2016 Jun;23(6):188-98. doi: 10.1038/cgt.2016.19. Epub 2016 May 20.

PMID:
27199222
12.

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.

Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP.

Cancer Gene Ther. 2016 May;23(5):142-8. doi: 10.1038/cgt.2016.14. Epub 2016 Apr 15.

13.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

14.

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, Junghans RP.

Clin Cancer Res. 2015 Jul 15;21(14):3149-59. doi: 10.1158/1078-0432.CCR-14-1421. Epub 2015 Apr 7.

15.

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.

Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N, Junghans RP, Katz SC.

Cancer Immunol Immunother. 2015 Jul;64(7):817-29. doi: 10.1007/s00262-015-1692-6. Epub 2015 Apr 8.

16.

T cell exhaustion and Interleukin 2 downregulation.

Balkhi MY, Ma Q, Ahmad S, Junghans RP.

Cytokine. 2015 Feb;71(2):339-47. doi: 10.1016/j.cyto.2014.11.024. Epub 2014 Dec 13. Review.

PMID:
25516298
17.

Recombination-deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution.

Im EJ, Bais AJ, Yang W, Ma Q, Guo X, Sepe SM, Junghans RP.

Mol Ther Methods Clin Dev. 2014 Jul 9;1:14022.

18.

Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.

Saied A, Licata L, Burga RA, Thorn M, McCormack E, Stainken BF, Assanah EO, Khare PD, Davies R, Espat NJ, Junghans RP, Katz SC.

Cancer Gene Ther. 2014 Nov;21(11):457-62. doi: 10.1038/cgt.2014.50. Epub 2014 Oct 3.

19.

A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.

MacLean AG, Walker E, Sahu GK, Skowron G, Marx P, von Laer D, Junghans RP, Braun SE.

J Med Primatol. 2014 Oct;43(5):341-8. doi: 10.1111/jmp.12137. Epub 2014 Aug 20.

20.

Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.

Al-Homsi AS, Lai Z, Roy TS, Al-Malki MM, Kouttab N, Junghans RP.

Transpl Immunol. 2014 Jan;30(1):40-5. doi: 10.1016/j.trim.2013.11.003. Epub 2013 Nov 19.

PMID:
24262132
21.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
22.

Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.

Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP.

Virology. 2013 Nov;446(1-2):268-75. doi: 10.1016/j.virol.2013.08.002. Epub 2013 Sep 6.

23.

Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils.

Licata LA, Nguyen CT, Burga RA, Falanga V, Espat NJ, Ayala A, Thorn M, Junghans RP, Katz SC.

J Leukoc Biol. 2013 Oct;94(4):813-23. doi: 10.1189/jlb.0313137. Epub 2013 Jul 24.

24.

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor.

Katz SC, Burga RA, Naheed S, Licata LA, Thorn M, Osgood D, Nguyen CT, Espat NJ, Fletcher JA, Junghans RP.

J Transl Med. 2013 Feb 21;11:46. doi: 10.1186/1479-5876-11-46.

25.

The emerging role of protein kinase Cθ in cytoskeletal signaling.

Michalczyk I, Sikorski AF, Kotula L, Junghans RP, Dubielecka PM.

J Leukoc Biol. 2013 Mar;93(3):319-27. doi: 10.1189/jlb.0812371. Epub 2012 Nov 27. Review.

26.

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H, Junghans RP, Sampath P.

Clin Cancer Res. 2012 Nov 1;18(21):5949-60. doi: 10.1158/1078-0432.CCR-12-0319. Epub 2012 Sep 10.

27.

Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis.

Katz SC, Ryan K, Ahmed N, Plitas G, Chaudhry UI, Kingham TP, Naheed S, Nguyen C, Somasundar P, Espat NJ, Junghans RP, Dematteo RP.

J Immunol. 2011 Aug 1;187(3):1150-6. doi: 10.4049/jimmunol.1004077. Epub 2011 Jun 22.

28.

Autoimmunity associated with immunotherapy of cancer.

Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH.

Blood. 2011 Jul 21;118(3):499-509. doi: 10.1182/blood-2011-01-325266. Epub 2011 Apr 29. Review. Erratum in: Blood. 2012 Dec 20;120(26):5251.

PMID:
21531979
29.

Is it safer CARs that we need, or safer rules of the road?

Junghans RP.

Mol Ther. 2010 Oct;18(10):1742-3. doi: 10.1038/mt.2010.162. No abstract available.

30.

Cell density plays a critical role in ex vivo expansion of T cells for adoptive immunotherapy.

Ma Q, Wang Y, Lo AS, Gomes EM, Junghans RP.

J Biomed Biotechnol. 2010;2010:386545. doi: 10.1155/2010/386545. Epub 2010 Jun 30.

31.

Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies.

Junghans RP.

J Transl Med. 2010 Jun 10;8:55. doi: 10.1186/1479-5876-8-55.

32.

Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.

Lo AS, Ma Q, Liu DL, Junghans RP.

Clin Cancer Res. 2010 May 15;16(10):2769-80. doi: 10.1158/1078-0432.CCR-10-0043. Epub 2010 May 11.

33.

Dystrophia myotonia: why focus on foci?

Junghans RP.

Eur J Hum Genet. 2009 May;17(5):543-53. doi: 10.1038/ejhg.2008.227. Epub 2009 Jan 28.

34.
35.

Sorting vector producer cells for high transgene expression increases retroviral titer.

Beaudoin EL, Bais AJ, Junghans RP.

J Virol Methods. 2008 Mar;148(1-2):253-9. doi: 10.1016/j.jviromet.2007.12.008. Epub 2008 Feb 4.

PMID:
18249448
36.

Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML).

Yang W, Beaudoin EL, Lu L, Du Pasquier RA, Kuroda MJ, Willemsen RA, Koralnik IJ, Junghans RP.

Int Immunol. 2007 Sep;19(9):1083-93. Epub 2007 Jul 28.

PMID:
17660502
37.

Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers.

Wang Y, Ylera F, Boston M, Kang SG, Kutok JL, Klein-Szanto AJ, Junghans RP.

Breast Cancer Res Treat. 2007 Aug;104(2):129-44. Epub 2007 Mar 28.

PMID:
17393302
38.

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG, Waldmann TA, Junghans RP.

Leuk Res. 2006 Feb;30(2):190-203. Epub 2005 Sep 13.

PMID:
16165209
39.

Functional analysis of the mouse Fcgrt 5' proximal promoter.

Tiwari B, Junghans RP.

Biochim Biophys Acta. 2005 Jan 11;1681(2-3):88-98. Epub 2004 Nov 24.

PMID:
15627500
40.

Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.

Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP.

Prostate. 2004 Sep 15;61(1):12-25.

PMID:
15287090
42.

RNA leaching of transcription factors disrupts transcription in myotonic dystrophy.

Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP.

Science. 2004 Jan 16;303(5656):383-7. Epub 2003 Dec 4.

43.

Genetically engineered T cells as adoptive immunotherapy of cancer.

Ma Q, Gonzalo-Daganzo RM, Junghans RP.

Cancer Chemother Biol Response Modif. 2002;20:315-41. Review. No abstract available.

PMID:
12703212
44.

Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity.

Emtage PC, Clarke D, Gonzalo-Daganzo R, Junghans RP.

J Immunother. 2003 Mar-Apr;26(2):97-106. Erratum in: J Immunother. 2003 May-Jun;26(3):290. Gonzalo-Dagonzo Rosa [corrected to Gonzalo-Daganzo Rosa].

PMID:
12616101
45.

Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer.

Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP.

Cancer Res. 2001 Nov 1;61(21):7889-99.

46.
47.

Biventricular cardiac thrombosis during interleukin-2 infusion.

Junghans RP, Manning W, Safar M, Quist W.

N Engl J Med. 2001 Mar 15;344(11):859-60. No abstract available.

PMID:
11252319
48.

Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP.

Neoplasia. 2000 Sep-Oct;2(5):449-59.

49.

Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death.

Beecham EJ, Ma Q, Ripley R, Junghans RP.

J Immunother. 2000 Nov-Dec;23(6):631-42.

PMID:
11186151
50.

Direct immunoprecipitation of antigen with phage displaying immunoglobulin fragment.

Telleman P, Kingsbury GA, Junghans RP.

Biotechniques. 2000 Dec;29(6):1240-2, 1244, 1246 passim.

Supplemental Content

Loading ...
Support Center